Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Background:We recently reported encouraging antileukemic activity of venetoclax, an orally available selective BCL-2 inhibitor, in combination with hypomethylating agents (HMA; NCT02203773) or low dose cytarabine (LDAC; NCT02287233) in patients aged ≥65 years with treatment-naive acute myeloid leukemia (AML) who are not fit for standard induction therapy [Pollyea et al, ASCO 2016 (abstract 7009); Lin et al, ASCO 2016 (abstract 7007)]. Here we present the genetic and molecular markers observed in this patient population, and their correlation with responses.